一氧化氮对脊髓和背根神经节神经元的体外存活及活性作用研究

本文应用免疫细胞化学及ＮＳＥ－ＥＬＩＳＡ方法观察了一氧化氮对体外培养脊髓和背根神经节神经元的存活及对活性的影响。结果表明：一氧化氮合酶抑制剂Ｎ－Ａｒｇ组（１００、２００μｍｏｌ／Ｌ）ＮＳＥ免疫反应阳性神经元数目、面积（ＡＦ值）及活性（ＯＤ值）明显大于空白对照组（Ｐ＜０．０１）。而一氧化氮合酶底物Ｌ－Ａｒｇ组（１ｍｍｏｌ／Ｌ）神经元面积积分和活性则小于对照组（Ｐ＜０．０１）。Ｌ－Ａｒｇ的细胞毒性作用可为Ｎ－Ａｒｇ逆转。     

Clinical observation on treatment of tubal pregnancy by chinese herbal medicine combined with tubal intubation administration of methotrexate under uteroscope

Ｔｈｅｄｉａｇｎｏｓｔｉｃｍｅｔｈｏｄｏｆｅａｒｌｙｔｕｂａｌｐｒｅｇｎａｎｃｙｈａｓｂｅｅｎｉｍｐｒｏｖｅｄｐｒｏｇｒｅｓｓｉｖｅｌｙｉｎｒｅｃｅｎｔｙｅａｒｓ,ａｎｄｍｏｒｅａｔｔｅｎｔｉｏｎｉｓｐａｉｄｔｏｃｏｎｓｅｒｖａｔｉｖｅｔｈｅｒａｐｙｏｆｔｈｅｄｉｓｅａｓｅ．ＣｏｍｂｉｎａｔｉｏｎｔｈｅｒａｐｙｏｆＣｈｉｎｅｓｅｈｅｒｂａｌｍｅｄｉｃｉｎｅ（ＣＨＭ）ｆｏｒａｃｔｉｖａｔｉｎｇｂｌｏｏｄｃｉｒｃｕｌａｔｉｏｎｔｏｒｅｍｏｖｅｂｌｏｏｄｓｔａｓｉｓａｎｄｍｅｔｈｏｔｒｅｘａｔｅ（ＭＴ…     

腹膜透析治疗小儿先天性心脏病术后急性肾功能衰竭

目的：探讨腹膜透析（ＰＤ）对小儿先天性心脏病（先心病）术后急性肾功能衰竭（ＡＲＦ）的治疗效果。方法：对３６例先心病术后ＡＲＦ行ＰＤ治疗患儿的临床资料作回顾性调查。结果：全组经ＰＤ治疗后的病死率为３０．６％,其中单纯ＡＲＦ的病死率１２．５％,显著低于合并其他系统器官衰竭组的４５％（Ｐ〈０．０５）。ＰＤ３～３０ｄ内肾功能恢复,其中１～２ｄ内血Ｋ＾＋恢复正常,２～５ｄ内血碳酸氢根（ＨＣＯ３＾－）恢复正常,４～６ｄ内血尿素氮下降４９．２％,血肌酐下降４２．６％。结论：对小儿先心病术后ＡＲＦ及早进行ＰＤ具有较好的治疗效果。     

Molecular evolution of SARS-CoV-2 from December 2019 to August 2022

Severe acute respiratorysyndrome coronavirus-2 (SARS-CoV-2) pandemic spread rapidly and this scenario is concerning worldwide, presenting more than 590 million coronavirus disease 2019 cases and 6.4 million deaths. The emergence of novel lineages carrying several mutations in the spike protein has raised additional public health concerns worldwide during the pandemic. The present study review and summarizes the temporal spreading and molecular evolution of SARS-CoV-2 clades and variants worldwide. The evaluation of these data is important for understanding the evolutionary histories of SARSCoV-2 lineages, allowing us to identify the origins of each lineage of this virus responsible for one of the biggest pandemics in history. A total of 2897 SARS-CoV-2 whole-genome sequences with available information from the country and sampling date (December 2019 to August 2022), were obtained and were evaluated by Bayesian approach. The results demonstrated that the SARS-CoV-2 the time to the most recent common ancestor (tMRCA) in Asia was 2019-12-26 (highest posterior density 95% [HPD95%]: 2019-12-18; 2019-12-29), in Oceania 2020-01-24 (HPD95%: 2020-01-15; 2020-01-30), in Africa 2020-02-27 (HPD95%: 2020-02-21; 2020-03-04), in Europe 2020-02-27 (HPD95%: 2020-02-20; 2020-03-06), in North America 2020-03-12 (HPD95%: 2020-03-05; 2020-03-18), and in South America 2020-03-15 (HPD95%: 2020-03-09; 2020-03-28). Between December 2019 and June 2020, 11 clades were detected (20I [Alpha] and 19A, 19B, 20B, 20C, 20A, 20D, 20E [EU1], 20F, 20H [Beta]). From July to December 2020, 4 clades were identified (20J [Gamma, V3], 21 C [Epsilon], 21D [Eta], and 21G [Lambda]). Between January and June 2021, 3 clades of the Delta variant were detected (21A, 21I, and 21J). Between July and December 2021, two variants were detected, Delta (21A, 21I, and 21J) and Omicron (21K, 21L, 22B, and 22C). Between January and June 2022, the Delta (21I and 21J) and Omicron (21K, 21L, and 22A) variants were detected. Finally, between July and August 2022, 3 clades of Omicron were detected (22B, 22C, and 22D). Clade 19A was first detected in the SARS-CoV-2 pandemic (Wuhan strain) with origin in 2019-12-16 (HPD95%: 2019-12-15; 2019-12-25); 20I (Alpha) in 2020-11-24 (HPD95%: 2020-11-15; 2021-12-02); 20H (Beta) in 2020-11-25 (HPD95%: 2020-11-13; 2020-11-29); 20J (Gamma) was 2020-12-21 (HPD95%: 2020-11-05; 2021-01-15); 21A (Delta) in 2020-09-20 (HPD95%: 2020-05-17; 2021-02-03); 21J (Delta) in 2021-02-26 (2020-11-02; 2021-04-24); 21M (Omicron) in 2021-01-25 (HPD95%: 2020-09-16; 2021-08-08); 21K (Omicron) in 2021-07-30 (HPD95%: 2021-05-30; 2021-10-19); 21L (Omicron) in 2021-10-03 (HPD95%: 2021-04-16; 2021-12-23); 22B (Omicron) in 2022-01-25 (HPD95%: 2022-01-10; 2022-02-05); 21L in 2021-12-20 (HPD95%: 2021-05-16; 2021-12-31). Currently, the Omicron variant predominates worldwide, with the 21L clade branching into 3 (22A, 22B, and 22C). Phylogeographic data showed that Alpha variant originated in the United Kingdom, Beta in South Africa, Gamma in Brazil, Delta in India, Omicron in South Africa, Mu in Colombia, Epsilon in the United States of America, and Lambda in Peru. The COVID-19 pandemic has had a significant impact on global health worldwide and the present study provides an overview of the molecular evolution of SARS-CoV-2 lineage clades (from the Wuhan strain to the currently circulating lineages of the Omicron).     

不同来源精子单精子卵胞浆内注射治疗不育症

目的：采用不同来源精子行单精子卵胞浆内注射术（ＩＣＳＩ）治疗不育症并进行疗效对比观察,方法：女性行常规超促排卵和经阴道超声引导下取卵。比较采用精液、附睾和睾丸精子行ＩＣＳＩ后的卵子损伤率、受精率、卵裂率、胚胎质量和临床妊娠率。结果：５３对不育夫妇共行６２仆ＩＣＳＩ周期。２７例临床妊娠,周期临床妊娠率为４３．５％,分别有３６、１２和１４个周期采用精液、附睾和睾丸精子,三组的卵子损伤率、受精率、卵裂率     

Nasotracheal enterococcal carriage and resistomes: detection of optrA-, poxtA- and cfrD-carrying strains in migratory birds,livestock, pets,and in-contact humans in Spain

European Journal of Clinical Microbiology & Infectious Diseases - This study determined the carriage rates and antimicrobial resistance (AMR) genes of enterococci from...     

中剂量特尔立(rhGM-CSF)防治肿瘤化疗所致白细胞减少的疗效观察

目的观察中剂量特尔立(rhGM-CSF)对恶性肿瘤化疗后白细胞减少的防治作用.方法采用自身对照,化疗过程中白细胞降至正常值(4.0×109/L)以下时入组,并作为对照周期.其后的化疗周期中末次给药48小时后皮下注射rhGM-CSF(150ug/(次.天).结果 rhGM-CSF能明显减轻化疗后白细胞下降的程度,缩短白细胞在正常值以下的持续时间及恢复到正常值以上的时间,对血小板的变化影响不大,毒副反应轻微.结论使用特尔立(rhGM-CSF)安全、有效,可作为肿瘤化疗有价值的辅助药物.     

化疗在晚期肺腺癌治疗中的作用

目的：探索晚期肺腺癌患者化疗疗效和对化疗的耐受性,化疗后生活质量变化和生存期。材料与方法：回顾分析1992－11~1995-04,经病理确诊为肺腺癌。按UICC分期为Ⅲb、Ⅳ期,Kamofsky评分≥60,连续完成2程以上的以铂类药物为主的联合化疗方案治疗患者。结果：化疗有效率3．1％,化疗后Kamofskv评分不变者43．8％,升高40．6％。下降≥10分15．6％,Ⅲb期中位生存期13月,Ⅳ期10月。结论：全身状况较好无化疗禁忌证的晚期肺腺癌患者,给予适当的联合化疗可使部分患者病情改善,生活质量提高。     

Bilateral macular hemorrhage after laser in situ keratomileusis

· Background: This is the first report of a bilateral submacular hemorrhage after LASIK surgery in an extreme myo pic patient. A 31-year-old man underwent bilateral surgery for correction of –16.75+0.75×70° and –16.50+0.50×55°. · Methods: Case report. · Results: One day after surgery the patient’s uncorrected visual acuity was in the 20/50 range OU and by 17 days after surgery his visual acuity had declined to 20/200 range. Fundus examination showed multifocal subretinal macular and posterior pole hemorrhages. Fluorescein angiography showed some macular lesions compatible with lacquer cracks. · Conclusions: Preoperative and postoperative fundus examination is important to detect this phenomenon. Patients should be informed of this rare complication. Received: 2 June 1998 Revised version received: 16 November 1998 Accepted: 17 November 1998